192 related articles for article (PubMed ID: 34796106)
1. Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model.
Shao D; Du D; Liu H; Lv J; Cheng Y; Zhang H; Lv W; Wang S; Lu L
Front Oncol; 2021; 11():721318. PubMed ID: 34796106
[TBL] [Abstract][Full Text] [Related]
2. Development and Validation of a Machine Learning Model to Explore Tyrosine Kinase Inhibitor Response in Patients With Stage IV EGFR Variant-Positive Non-Small Cell Lung Cancer.
Song J; Wang L; Ng NN; Zhao M; Shi J; Wu N; Li W; Liu Z; Yeom KW; Tian J
JAMA Netw Open; 2020 Dec; 3(12):e2030442. PubMed ID: 33331920
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
[TBL] [Abstract][Full Text] [Related]
4. A New Approach to Predict Progression-free Survival in Stage IV EGFR-mutant NSCLC Patients with EGFR-TKI Therapy.
Song J; Shi J; Dong D; Fang M; Zhong W; Wang K; Wu N; Huang Y; Liu Z; Cheng Y; Gan Y; Zhou Y; Zhou P; Chen B; Liang C; Liu Z; Li W; Tian J
Clin Cancer Res; 2018 Aug; 24(15):3583-3592. PubMed ID: 29563137
[No Abstract] [Full Text] [Related]
5. CT-Based Radiomic Signature as a Prognostic Factor in Stage IV
Li H; Zhang R; Wang S; Fang M; Zhu Y; Hu Z; Dong D; Shi J; Tian J
Front Oncol; 2020; 10():57. PubMed ID: 32133282
[No Abstract] [Full Text] [Related]
6. PET/CT Radiomic Features: A Potential Biomarker for EGFR Mutation Status and Survival Outcome Prediction in NSCLC Patients Treated With TKIs.
Yang L; Xu P; Li M; Wang M; Peng M; Zhang Y; Wu T; Chu W; Wang K; Meng H; Zhang L
Front Oncol; 2022; 12():894323. PubMed ID: 35800046
[TBL] [Abstract][Full Text] [Related]
7. Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors.
Wang TW; Chao HS; Chiu HY; Lu CF; Liao CY; Lee Y; Chen JR; Shiao TH; Chen YM; Wu YT
Transl Oncol; 2024 Jan; 39():101826. PubMed ID: 37984256
[TBL] [Abstract][Full Text] [Related]
8. Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.
Zhang X; Lu B; Yang X; Lan D; Lin S; Zhou Z; Li K; Deng D; Peng P; Zeng Z; Long L
Eur Radiol; 2023 Feb; 33(2):825-835. PubMed ID: 36166088
[TBL] [Abstract][Full Text] [Related]
9. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
[TBL] [Abstract][Full Text] [Related]
10. Value of interim
Shao D; Cheng Y; Yuan ZS; Jiang BY; Wang SX
Lung Cancer; 2020 Nov; 149():137-143. PubMed ID: 33011375
[TBL] [Abstract][Full Text] [Related]
11. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
[TBL] [Abstract][Full Text] [Related]
12. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
13. Value of
Yang B; Ji H; Zhong J; Ma L; Zhong J; Dong H; Zhou C; Duan S; Zhu C; Tian J; Zhang L; Wang F; Zhu H; Lu G
Front Oncol; 2020; 10():567160. PubMed ID: 33262942
[TBL] [Abstract][Full Text] [Related]
14. Development and Validation of a Radiomics Nomogram Based on
Yang B; Zhong J; Zhong J; Ma L; Li A; Ji H; Zhou C; Duan S; Wang Q; Zhu C; Tian J; Zhang L; Wang F; Zhu H; Lu G
Front Oncol; 2020; 10():1042. PubMed ID: 32766134
[No Abstract] [Full Text] [Related]
15. A radiomics prognostic scoring system for predicting progression-free survival in patients with stage IV non-small cell lung cancer treated with platinum-based chemotherapy.
He L; Li Z; Chen X; Huang Y; Yan L; Liang C; Liu Z
Chin J Cancer Res; 2021 Oct; 33(5):592-605. PubMed ID: 34815633
[TBL] [Abstract][Full Text] [Related]
16. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC.
Zhang Y; Zeng L; Zhang X; Li Y; Liu L; Xu Q; Yang H; Jiang W; Lizaso A; Qiu L; Hou T; Liu J; Peng L; Yang N
BMC Med; 2021 Oct; 19(1):245. PubMed ID: 34663309
[TBL] [Abstract][Full Text] [Related]
18. Value of pre-therapy
Zhang J; Zhao X; Zhao Y; Zhang J; Zhang Z; Wang J; Wang Y; Dai M; Han J
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1137-1146. PubMed ID: 31728587
[TBL] [Abstract][Full Text] [Related]
19. Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations.
Dong J; Tong S; Shi X; Wang C; Xiao X; Ji W; Sun Y
Cancer Manag Res; 2020; 12():13607-13616. PubMed ID: 33447080
[TBL] [Abstract][Full Text] [Related]
20. Radiomics Analysis of PET and CT Components of
Wang X; Lu Z
Front Oncol; 2021; 11():638124. PubMed ID: 33928029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
